Core Viewpoint - The announcement from Zhenjiang Co., Ltd. regarding the share reduction plan by shareholder Hu Zhen indicates a strategic move driven by personal funding needs, potentially impacting the company's stock performance and investor sentiment [1][2]. Share Reduction Plan - Hu Zhen plans to reduce his holdings by up to 5,529,039 shares, representing a maximum of 3% of the total share capital, within three months following the announcement [1]. - The reduction will occur through both centralized bidding and block trading, with specific limits on the number of shares that can be sold in any 90-day period [1]. - The selling price will be determined by the market price at the time of the reduction, and adjustments will be made if there are changes in share capital due to stock dividends or capital increases [1]. Current Shareholding Structure - As of the announcement date, Hu Zhen holds 41,206,155 shares, accounting for 22.36% of the total share capital [2]. - Other significant shareholders include Bu Chunhua with 1,300,000 shares (0.71%) and Jiangyin Zhenjiang Langwei Investment Co., Ltd. with 9,054,107 shares (4.91%) [2]. Financial Implications - Based on the closing price of 28.50 CNY per share on September 29, the estimated amount from Hu Zhen's planned reduction is approximately 158 million CNY [2]. - Hu Zhen has previously reduced his holdings, with a total of 559,260 shares sold since September 30, 2021, resulting in cash proceeds of about 17.78 million CNY [3][4].

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Viewpoint - Zhenjiang Co., Ltd. (603507.SH) experienced a significant decline in stock price, dropping 6.32% to 26.7 yuan, resulting in a market capitalization falling below 5 billion yuan due to a share reduction announcement by shareholder Hu Zhen [1] Group 1: Shareholder Actions - Shareholder Hu Zhen plans to reduce his holdings by no more than 5.529 million shares, which represents up to 3% of the company's total share capital [1] - As of the announcement date, Hu Zhen holds 41,206,155 shares, accounting for 22.36% of the company's total share capital [1] Group 2: Financial Performance - The company reported a significant increase in non-recurring losses from foreign exchange hedging in the first half of the year, which has directly impacted current profits [1]

Core Viewpoint - Several companies are planning to reduce their shareholdings, indicating potential shifts in ownership and investor sentiment in the market [1] Shareholder Reductions - Senba Sensor's actual controller's concerted action party plans to reduce holdings by no more than 1.09% [1] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [1] - Andeli's shareholder BVI Donghua plans to reduce holdings by no more than 1.00% [1] - Zhiyang Innovation's controlling shareholder and its concerted action party plan to reduce a total of no more than 4.225 million shares [1] - Sichuan Gold's shareholder Beijing Jinyang intends to reduce holdings by no more than 1.8% [1] - Guoji Heavy Industry's shareholders, including Bank of China Deyang Branch and Bank of China Zhenjiang Runzhou Branch, plan to reduce a total of no more than 1% [1] - Meixin Sheng's shareholder WI Harper Fund VII plans to reduce holdings by no more than 1% [1] - Yanmian Technology's actual controller and controlling shareholder Liu Yan plan to reduce a total of 1.2897% of the company's shares [1] - Jingwei Henghai's supervisor Cui Wenge plans to reduce no more than 600,000 shares [1] - New Xiangwei's shareholder Kehongxin plans to reduce holdings by no more than 1% [1] - Wujin Stainless Steel's three executives plan to reduce a total of no more than 623,400 shares [1] - Zhongrun Optical's director Lu Gaofei plans to reduce no more than 695,300 shares [1] Regulatory Actions - *ST Mubang's actual controller Liao Zhiyuan has received a notice of investigation from the China Securities Regulatory Commission [1] - Youkeshu's shareholder has also received a notice of investigation from the China Securities Regulatory Commission [1]

Group 1 - Yinglian Co., Ltd. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531% to 1673% [1] - China CNR Corporation signed major contracts totaling approximately 54.34 billion yuan, accounting for 22% of its expected revenue for 2024 [1] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.1% [2] Group 2 - Fulian Precision plans to increase capital in its subsidiary Jiangxi Shenghua with a total investment of 35.63 billion yuan, which is expected to constitute a major asset restructuring [3] - Aimeike has obtained a drug registration certificate for Minoxidil topical solution, which is used for treating male pattern baldness [4] - Guolin Technology is planning to acquire 91.07% of Kailianjie’s equity for cash, which is expected to constitute a major asset restructuring [5] Group 3 - Baicheng Co. plans to purchase 55% of Shanghai Canxi Engineering Equipment Co. and will suspend trading of its stock starting September 30, 2025 [6][7] - Diaowei is planning to acquire equity in Rongpai Semiconductor and has suspended trading of its stock [8] - Xiatun New Energy signed a strategic cooperation framework agreement with Zhongwei Co. to establish a long-term partnership in the supply chain for solid-state lithium battery materials [9] Group 4 - Lingyi Zhi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [10] - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, which targets cancer pain treatment [11] - Weide Information announced a preliminary transfer price of 40.33 yuan per share, representing a 26% discount to its closing price [12] Group 5 - Huayou Cobalt's subsidiary signed contracts with LGES for the supply of 76,000 tons of ternary precursor materials and 88,000 tons of ternary cathode materials from 2026 to 2030 [13] - Hubei Energy signed a cooperation agreement with the Xiangyang Municipal Government to invest 26.7 billion yuan in clean energy projects [14]

Core Viewpoint - Zhenjiang Co., Ltd. (603507.SH) announced that Mr. Hu Zhen plans to reduce his shareholding in the company due to personal funding needs, with a total reduction not exceeding 5.529 million shares, which is 3% of the total share capital [1] Summary by Category - **Share Reduction Plan** - Mr. Hu Zhen intends to reduce his holdings through centralized bidding and block trading methods, with a total of up to 5.529 million shares [1] - The reduction will occur within three months starting from 15 trading days after the announcement [1] - **Trading Method Details** - In the case of centralized bidding, the total number of shares reduced within any consecutive 90 days will not exceed 1.843 million shares (1% of total share capital) [1] - For block trading, the total number of shares reduced within any consecutive 90 days will not exceed 3.686 million shares (2% of total share capital) [1] - **Pricing Mechanism** - The reduction price will be determined based on the market price at the time of the reduction [1]

Core Viewpoint - Hu Zhen, a shareholder holding 22.36% of Zhenjiang Co., plans to reduce his stake by up to 5.529 million shares, representing no more than 3% of the company's total share capital through centralized bidding and block trading [1] Group 1 - Hu Zhen's planned share reduction is significant as it involves a substantial portion of his holdings [1] - The reduction will be executed through two methods: centralized bidding and block trading [1] - The total number of shares to be reduced is capped at 5.529 million [1]

证券代码：603507 证券简称：振江股份 公告编号：2025-064 江苏振江新能源装备股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持主体持股的基本情况 截至本公告披露日，江苏振江新能源装备股份有限公司（以下简称"公司"） 股东胡震先生持有公司无限售条件流通股份 41,206,155 股，占公司总股本的 22.36%；卜春华女士持有公司无限售条件流通股 1,300,000 股，占公司总股本的 0.71%；江阴振江朗维投资企业(有限合伙)(以下简称"朗维投资")持有公司无限售 条件流通股 9,054,107 股，占公司总股本的 4.91%。 上述股东构成一致行动关系，合计持有公司股份 51,560,262 股，占公司总股 本的 27.98%。 减持计划的主要内容 胡震先生因自身资金需求，计划自本公告披露之日起 15 个交易日后的 3 个 月内，拟通过集中竞价、大宗交易方式合计减持公司股份不超过 5,529,039 股即 不超过公司总股本的 3%；其中，采取集中 ...

证券代码：603507 证券简称：振江股份 公告编号：2025-065 江苏振江新能源装备股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 15 日 （星期三） 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 30 日（星期二）至 10 月 14 日 （星期二）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 jznee@zjavim.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 江苏振江新能源装备股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大 ...

Core Viewpoint - Shareholder Hu Zhen of Zhenjiang Co., Ltd. plans to reduce his stake by up to 3% due to personal funding needs [1] Summary by Relevant Sections - **Shareholder Action** - Hu Zhen intends to reduce his holdings by a maximum of 5,529,039 shares, which represents no more than 3% of the company's total share capital [1]